Form 4: Biogen Executive Adam Keeney Reports Stock Transactions
SEC Form 4 Filing
Adam Keeney, Head of Corporate Development at Biogen, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.
Summary
- On May 1, 2025, Adam Keeney, Head of Corporate Development at Biogen, reported transactions involving Biogen common stock.
- Keeney exercised 938 restricted stock units (RSUs) that converted into common stock.
- Simultaneously, Keeney sold 454 shares of common stock at a price of $120.93 to satisfy tax withholding obligations related to the RSU vesting.
- Following these transactions, Keeney directly owns 2,384 shares of Biogen common stock and 939 derivative securities.
Sentiment
Score: 5
Explanation: The document reflects routine transactions related to executive compensation, with no indication of positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of compliance for corporate insiders, providing transparency into their transactions in company stock. These filings are closely watched by investors seeking insights into management's perspective on the company's valuation and future prospects.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they are part of standard executive compensation practices.
- The filing provides transparency to shareholders regarding insider transactions.
Key Dates
| Date | Description |
|---|---|
| 05/01/2023 | Grant date of the restricted stock units, which vest in three equal yearly installments beginning on the first anniversary. |
| 05/01/2025 | Date of transaction: vesting of restricted stock units and sale of shares. |
| 05/01/2026 | Expiration date of the restricted stock units. |
| 05/05/2025 | Date of signature on the Form 4 filing. |
Keywords
Form 4, Biogen, BIIB, Stock Transaction, Restricted Stock Units, Insider Trading, Adam Keeney, Corporate Development
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.